Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, ...

Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential ...

Pfizer (NYSE:PFE) stock is a biopharmaceutical firm that had a magnificent breakout in 2021 as the worst of the pandemic sent ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

However, in the 18 months since, a number of ex-Pfizer employees have led the formation of a variety of startups which, with ...